Bisphosphonates and denosumab are similarly effective. Over 1 to 4 years,
bisphosphonates or denosumab provide an absolute reduction of about 0.5% to 1.0% for hip …

For postmenopausal women with osteoporosis, initiating treatment is vital to increasing bone
mineral density and avoiding bone fragility, which can lead to fractures. Long-term treatment …

Key Clinical Points Postmenopausal Osteoporosis Fractures and osteoporosis are common,
particularly among older women, and hip fractures can be devastating. Treatment is …

Approximately 10 million men and women in the US have osteoporosis, 1 a metabolic bone
disease characterized by low bone density and deterioration of bone architecture that …

John Hunter, a British surgeon, first discovered osteoporosis in the 1800s, a condition that
predominantly affects post-menopausal women. Over the years the perception of post …

Efficacy of treatment with bisphosphonates as a sequential treatment compared with continuous
use of denosumab in postmenopausal women with osteoporosis - 대한산부인과학회 학술발표 …

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture,
resulting in increased fracture risk. Several therapeutic agents are now available to treat …

In postmenopausal women, osteoporotic fractures are more common than stroke,
myocardial infarction, and breast cancer combined, and fractures can be costly and result in …

CONCLUSIONS• This study assessed the effectiveness of denosumab and
bisphosphonates among women with postmenopausal osteoporosis in routine clinical …

Objective: The purpose of this study was to examine the effectiveness of denosumab to treat
postmenopausal osteoporosis, and the impact of prior osteoporosis drug use and the …